PRDM1 targeted various NK-cell receptors and also bound genes of the signaling lymphocytic activation molecule (SLAM) family (Fig. 2C), which are crucial for regulating NK-cell activation and subsequent effector programs when encountering pathogens or tumor cells and for restraining the effector functions upon ligation to MHC class I molecules [54]. The gene discussed is SLAMF1; the disease is neoplasm.